Address
NYtor B.V.
Berg en Dalseweg 199
6522 BJ Nijmegen
the Netherlands
Contact
Han Zendman+31646255462
Han.zendman@nytor.nl
Website
Partner in smart MDx assay development
Multiplex qPCR - Point of Care Applications - Antibiotic Resistance Detection
NYtor designs and develops molecular detection assays in the field of human and veterinary infectious disease diagnostics. Our main focus is the development of smart molecular assays for the detection of antibiotic resistance.
Tailor-made applications and approaches. NYtor is a reliable business partner, focusing on long-term relationships based on personal interactions.
- Microbial diagnostics
- Infection prevention
- Antimicrobial stewardship
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- Co-develop
- License
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
Organisation looking for support in development and route to market of molecular diagnostic assays.
NYtor employs an enthusiastic and motivated team of PhDs and technicians with ample experience and state-of-the-art knowledge of MDx assay development
Assays available for commercialization:
STIs:
• NG + quinolone resistance
• MG + macrolide and quinolone resistance
CPE/ESBL:
• CPE : KPC, OXA48 (including OXA181), VIM and NDM (+IMP)
• ESBL : CTX-M-1; CTX-M-2; CTX-M-9 groups and SHV-ESBL
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!